focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 23.20
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 2.80 (12.069%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

30 Nov 2016 17:47

RNS Number : 6216Q
Oncimmune Holdings PLC
30 November 2016
 

30 November 2016

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR

 

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 30 November 2016, options over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to Dan Calvo, President of Oncimmune (USA) LLC, a PDMR, as well as to certain other US staff, under the Company's Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009) as follows:

 

Name

Position

Number of share options awarded

Option exercise price per share (pence)

Interest in issued share capital (%)

Dan Calvo

President of Oncimmune (USA) LLC

10,151

118.5

0.02

 

The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 29 November 2017 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 118.5 pence, being the mid-market closing price of the Ordinary Shares on 29 November 2016

 

For further information:

 

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

+44 (0) 203 829 5000

 

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name 

Dan Calvo

2

Reason for the notification

a)

Position/status 

President of Oncimmune (USA) LLC

b)

Initial notification/Amendment

 

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oncimmune Holdings plc

b)

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

options over Ordinary Shares - Oncimmune Holdings Plc Incentive Stock Option Plan

 

ISIN GB00BYQ94H38

b)

Nature of the transaction

 

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

N/A

10,151

d)

Aggregated information

 

Price(s)

Volume(s)

N/A

10,151

e)

Date of the transaction

 

30 November 2016

f)

Place of the transaction 

N/A

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHURSBRNNAAOAA
Date   Source Headline
17th May 202410:11 amRNSInvestor Presentation via Investor Meet Company
9th May 20243:08 pmRNSHolding(s) in Company
26th Apr 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
25th Apr 202410:44 amRNSHolding(s) in Company
2nd Apr 202411:34 amRNSResult of General Meeting
2nd Apr 20248:00 amRNSTotal Voting Rights
26th Mar 202411:18 amRNSHolding(s) in Company
13th Mar 20245:32 pmRNSBlock Listing Return
6th Mar 20243:02 pmRNSPosting of Notice of General Meeting
1st Mar 20241:00 pmRNSInvestor Presentation via Investor Meet Company
29th Feb 202411:19 amRNSHolding(s) in Company
29th Feb 20247:00 amRNSFinal Results
26th Feb 202411:30 amRNSResult of AGM
2nd Feb 20247:00 amRNSNotice of AGM
11th Dec 20233:12 pmRNSDirector/PDMR Shareholding
8th Dec 20232:31 pmRNSGrant of Options and PDMR Dealing
30th Nov 20237:00 amRNSProgress against Strategy
10th Nov 202310:14 amRNSHolding(s) in Company
7th Nov 20234:11 pmRNSGrant of Options and PDMR Dealing
19th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
12th Oct 20237:00 amRNSUpdate on Strategy & Changes to the Board
1st Aug 20237:00 amRNSBoard Changes
14th Jul 20232:00 pmRNSCorrected unaudited interim results to 31 May 2022
12th Jul 20237:00 amRNSAppointment of new leadership team & board changes
26th Jun 202311:10 amRNSChange of registered office
23rd Jun 20237:00 amRNSTransition of Executive Leadership
15th Jun 20235:16 pmRNSCorrection to interim results
13th Jun 20237:45 amRNSHolding(s) in Company
5th Jun 20234:02 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSInterim Results
22nd May 20237:00 amRNSSale of Oncimmune Limited to Freenome
3rd Apr 20234:38 pmRNSHolding(s) in Company
27th Mar 202311:07 amRNSResult of GM
3rd Mar 20237:00 amRNSPosting of Annual Report and Notice of GM
27th Feb 20232:36 pmRNSResult of AGM
27th Feb 20237:00 amRNSFinal Results
23rd Feb 20237:00 amRNSAppointment of Joint Broker
17th Feb 20237:00 amRNSSiemens Healthineers Collaboration
3rd Feb 202311:50 amRNSNotice of AGM
31st Jan 20237:00 amRNSNotice of Results
13th Jan 20237:00 amRNSAppointment of Non-Executive Director
20th Dec 20227:00 amRNSImmunoINSIGHTS Trading Update
19th Dec 20221:35 pmRNSDirector/PDMR Shareholding
14th Dec 20222:00 pmRNSResult of Capital Raising
9th Dec 20221:30 pmRNSExtension of Capital Raising
7th Dec 20222:00 pmRNSProposed Placing and Subscription
4th Nov 20224:16 pmRNSGrant of Options and PDMR Dealing
21st Sep 20222:16 pmRNSPDMR Dealing
21st Sep 20227:00 amRNSUnaudited results for the 12 months to 31 May 2022
30th Aug 20223:53 pmRNSRevised Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.